“…Initially, Puchner et al [14] published in 2001 a successful induction of tolerance to IFX in 2 cases including a child, with prior anaphylactic reaction. Later, Duburque et al [15], Mourad et al [17], and Brennan et al [16] reported the successful induction of tolerance to IFX in, respectively, 10, 12, and 6 patients with CD and various other autoimmune diseases. More recently, a study evaluating the impact of IgE antibodies detection in the management of IFX retreatment showed an efficient induction of tolerance in 3 out of 4 patients [13].…”